COPENHAGEN, Denmark, November 24, 2022 - Bavarian Nordic A/S (OMX: BAVA) has today received information about the following transactions of the company's shares/related securities by persons holding managerial responsibilities and/or persons/companies closely associated with such.
| 1. | Details of the person discharging managerial responsibilities/person closely associated | ||
| a) | Name | Gerard van Odijk | |
| 2. | Reason for the notification | ||
| a) | Position/status | Chairman of the Board of Bavarian Nordic A/S | |
| b) | Initial notification/Amendment | Initial notification | |
| 3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
| a) | Name | Bavarian Nordic A/S | |
| b) | LEI | 2138006JCDVYIN6INP51 | |
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument, type of instrument Identification code | Shares DK0015998017 | |
| b) | Nature of the transaction | Sale | |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
| DKK 236.00 | 2,153 | ||
| d) | Aggregated information
| 2,153 DKK 508,108.00 | |
| e) | Date of the transaction | 2022-11-23 | |
| f) | Place of the transaction | Nasdaq Copenhagen A/S, XCSE | |
| 1. | Details of the person discharging managerial responsibilities/person closely associated | ||
| a) | Name | Gerard van Odijk | |
| 2. | Reason for the notification | ||
| a) | Position/status | Chairman of the Board of Bavarian Nordic A/S | |
| b) | Initial notification/Amendment | Initial notification | |
| 3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
| a) | Name | Bavarian Nordic A/S | |
| b) | LEI | 2138006JCDVYIN6INP51 | |
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument, type of instrument Identification code | Shares DK0015998017 | |
| b) | Nature of the transaction | Sale | |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
| DKK 236.00 | 850 | ||
| d) | Aggregated information
| 850 DKK 200,600.00 | |
| e) | Date of the transaction | 2022-11-24 | |
| f) | Place of the transaction | Nasdaq Copenhagen A/S, XCSE | |
About Bavarian Nordic
Bavarian Nordic is a fully integrated vaccines company focused on the development, manufacturing and commercialization of life-saving vaccines. We are a global leader in smallpox vaccines and have been a long-term supplier to the U.S. Government of a non-replicating smallpox vaccine, which has been approved by the FDA, also for the protection against monkeypox. The vaccine is also approved in Europe and Canada. Our commercial product portfolio furthermore contains market-leading vaccines against rabies and tick-borne encephalitis. Using our live virus vaccine platform technology, MVA-BN, we have created a diverse portfolio of proprietary and partnered product candidates designed to save and improve lives by unlocking the power of the immune system, including an Ebola vaccine, which is licensed to the Janssen Pharmaceutical Companies of Johnson & Johnson. We are also committed to the development of a next generation COVID-19 vaccine. For more information visit www.bavarian-nordic.com.
Contacts
Europe: Rolf Sass Sørensen, Vice President Investor Relations, Tel: +45 61 77 47 43
US: Graham Morrell, Paddock Circle Advisors, graham@paddockcircle.com, Tel: +1 781 686 9600
Company Announcement no. 42 / 2022
Attachment
- 2022-42-en (https://ml-eu.globenewswire.com/Resource/Download/e3db4ba6-478b-4580-8e46-20a52bc0c71e)
